Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
135 Results for "
ATR
" in MedChemExpress (MCE) Product Catalog:
Products (135)
135 Results for "ATR" in MCE Product Catalog:
Cat. No.: HY-100399AR
CAS No.: 133825-81-7
Synonyms: PD-132301 hydrochloride (Standard); ATR101 hydrochloride (Standard)
Research Areas:
Nevanimibe hydrochloride (Standard) is the analytical standard of Nevanimibe hydrochloride. This product is intended for research and analytical applications. Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .
Cat. No.: HY-153658
CAS No.: 1613196-89-6
Research Areas:
ATR-IN-27 (Compound I-G-12) is an ATR inhibitor with a Ki value greater than 0.01 μM but less than 1 μM. ATR-IN-27 sensitizes colorectal cancer cells to Cisplatin (HY-17394) .
Cat. No.: HY-187196
Target:
Research Areas:
ATR/AURKA-ligand 1 (Compound 8g) is a ATR/AURKA ligand. ATR/AURKA-ligand 1 serves as a target protein ligand for the synthesis of ATR/AURKA PROTAC degraders, such as Abd141 (HY-187195). ATR/AURKA-ligand 1 is applicable to the research of acute lymphoblastic leukemia .
Cat. No.: HY-172247
CAS No.: 2954923-16-9
ATR-IN-31 is a selective ATR kinase inhibitor with an IC50 of 7 nM. ATR-IN-31 does not significantly inhibit ATM kinase activity. ATR-IN-31 inhibits viability of prostate cancer cells.ATR-IN-31 can be used for the research of prostate cancer .
Cat. No.: HY-182016
CAS No.: 3126270-11-6
Target:
PROTACs ATM/ATR Checkpoint Kinase (Chk) Apoptosis DNA/RNA Synthesis Caspase Bcl-2 Family MDM-2/p53
Research Areas:
PROTAC ATR degrader-3 is a potent CRBN-based ATR PROTAC degrader with a DC50 of 127 nM. PROTAC ATR degrader-3 also degrades CHK1 with an DC50 of 135 nM. PROTAC ATR degrader-3 inhibits cancer cells proliferation, migration and invasion, triggers apoptosis and induces S phase arrest and DNA damage. PROTAC ATR degrader-3 achieves tumor growth inhibition in LoVo xenograft mouse model without apparent toxicity. PROTAC ATR degrader-3 can be used for the research of colorectal cancer .
Cat. No.: HY-182017
CAS No.: 3060178-60-8
Research Areas:
ATR ligand 2 (Compound 26) is a ATR PROTAC ligand. ATR ligand 2 can be conjugated with E3 ligase Ligand (HY-W077589A) and linker to synthesize PROTAC ATR degrader-3 (HY-182016) .
Cat. No.: HY-184293
PROTAC ATR degrader-4 is a PROTAC-based ATR kinase degrader, with a DC50 of 6.18 μM and a Dmax of 71.42% in LoVo cells. PROTAC ATR degrader-4 downregulates ATR protein expression, inducing nuclear envelope rupture, genomic instability, DNA damage and apoptosis. PROTAC ATR degrader-4 exhibits anti-tumor activity in xenograft tumor mouse models and can be used for the research of atm-deficient cancers .
Cat. No.: HY-182018
CAS No.: 3126270-19-4
Research Areas:
ATR ligand 2-CO-Ph-COOH (Compound 39) is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for ATR (HY-182017) and a PROTAC linker, which recruits E3 ligases. can be used for synthesis of PROTAC ATR degrader-3 (HY-182016) .
Cat. No.: HY-111451R
CAS No.: 1613200-51-3
Synonyms: M1774 (Standard); ATR inhibitor 1 (Standard)
Target:
Research Areas:
Tuvusertib (Standard) is the analytical standard of Tuvusertib (HY-111451). This product is intended for research and analytical applications. Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ .
Cat. No.: HY-181618
CAS No.: 2758113-98-1
Gavapsertib (compound A) is a ATR kinase inhibitor that can be used in tumor research .
Cat. No.: HY-111451S
Synonyms: M1774-d3; ATR inhibitor 1-d3
Cat. No.: HY-119225
CAS No.: 67427-51-4
Target:
Research Areas:
CBP-93872 is a G2 checkpoint inhibitor and a chemosensitizer. CBP-93872 specifically inhibits DNA double-strand break (DSB)-dependent, Nbs1-mediated ATR activation, without directly inhibiting ATR kinase activity or affecting ATR activation induced by other types of DNA damage; meanwhile, it suppresses the pathway between ATM and ATR activation, thereby reducing the autophosphorylation of ATR and the subsequent phosphorylation of Chk1. CBP-93872 does not inhibit DNA end resection at DSB sites. CBP-93872 induces cell death and enhances the cytotoxic effects of platinum-containing compounds and pyrimidine antimetabolites on cancer cells. CBP-93872 can be used in related research on p53-mutant cancers, colorectal cancer, and pancreatic cancer .
Cat. No.: HY-136270S
CAS No.: 1792214-00-6
Synonyms: VX-803-d8; M4344-d8; ATR inhibitor 2-d8
Cat. No.: HY-P7521A
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ANTXR1; FLJ10601; ANTXR Cell Adhesion Molecule 1; Tumor Endothelial Marker 8 Precursor; Anthrax Toxin Receptor 1; Anthrax Toxin Receptor; TEM8; ANTXR1 Protein; ATR; 2310008J16Rik; Tumor Endothelial Marker 8; 2810405N18Rik; FLJ21776; GAPO
Species:
Human
Source:
HEK293
Cat. No.: HY-184294
CAS No.: 3037598-39-0
Research Areas:
ZH25 is an ATR kinase inhibitor with antiproliferative activity against ATM-deficient cancer cells. ZH25 induces DNA damage, reduces G2/M phase cell proportion, upregulates γH2AX, Cleaved-Caspase3, and Cleaved-PARP. ZH25 functions as an ATR kinase binding ligand for ATR-PROTAC degrader design. ZH25 can be used for the research of atm-deficient cancer .
Cat. No.: HY-P705240
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ANTXR1; FLJ10601; ANTXR Cell Adhesion Molecule 1; Tumor Endothelial Marker 8 Precursor; Anthrax Toxin Receptor 1; Anthrax Toxin Receptor; TEM8; ANTXR1 Protein; ATR; 2310008J16Rik; Tumor Endothelial Marker 8; 2810405N18Rik; FLJ21776; GAPO
Species:
Human
Source:
HEK293
Cat. No.: HY-RS22238
Target:
Research Areas:
Mmab Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mmab gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-187195
Target:
Research Areas:
Abd141 is a dual PROTAC degrader of ATR and Aurora kinase A (AURKA), with DC50 values of 97.7 nM and 6.7 nM, respectively. Abd141 inhibits the proliferation of acute lymphoblastic leukemia cells. Abd141 can be used in the research of acute lymphoblastic leukemia .
Cat. No.: HY-13902R
CAS No.: 1232416-25-9
Synonyms: VE-822 (Standard); VX-970 (Standard); M6620 (Standard)
Berzosertib (Standard) is the analytical standard of Berzosertib (HY-13902). This product is intended for research and analytical applications. Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR Kinase inhibitor. Berzosertib blocks ATR Kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
Cat. No.: HY-N18301
CAS No.: 69506-79-2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
